Apolipoproteins: Good Markers for Cardiovacular Risk in Patients with Chronic Kidney Disease and Dyslipidemia

Tudor, Mirela Nicoleta; Mitrea, Adina; Popa, Simona; Zaharie, Sorin Ioan; Moța, Maria; Mola, Eugen

doi:10.2478/rjdnmd-2014-0023

Cited by 4 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Severe lipid metabolism disorders arise in patients with kidney failure and the lipid metabolism disorder peculiar to this patient group is known as uraemic dyslipidaemia, 5 which may accelerate its progression. 6 Abnormal lipid profile in CKD includes hypertriglyceridaemia, increase in triglyceride remnant Lp (a), increase in VLDL, decrease in HDL, total cholesterol and LDL usually within normal limits except in nephrotic syndrome patients. 7 The association between lipid profile and severity of CKD has rarely been studied in a general population, especially in our part of the country and may have a future prognostic and management implication in patients with CKD.…”

mentioning

confidence: 99%

Dyslipidaemia in CKD Patients and Its Correlation With Severity of Renal Dysfunction

Mohanty¹,

Acharya²,

Thatoi³

et al. 2018

jemds

View full text Add to dashboard Cite

BACKGROUND Chronic kidney disease (CKD) is a significant global health problem with significant morbidity and mortality. Dyslipidaemia along with an abnormal apolipoprotein profile and composition is a common complication associated with the decline in eGFR in CKD. The association between abnormal lipid profile and severity of CKD has rarely been studied in a general population, especially in Indian setup and may have a future prognostic and management implication in patients with CKD. Aims and Objectives-To study the pattern of lipid abnormalities in CKD patients and to correlate with severity of renal dysfunction. MATERIALS AND METHODSA descriptive comparative study was done using 50 cases of CKD of > 15 years age, along with 30 age and sex matched controls excluding confounding factors like diabetes, HTN, thyroid abnormalities, heart diseases, infection, inflammatory diseases, smoking, alcoholism etc. History, general and systemic examination, routine blood parameters, ECG, USG abdomen pelvis, serum total cholesterol, LDL, HDL, VLDL and triglycerides were done. The eGFR was calculated according to the CKD-EPI equation. Statistical analysis was done using student's t-test, ANOVA, Bonferroni test, Mann-Whitney U test, Chi-square test and Pearson's correlation. P value < 0.05 was considered as statistically significant. RESULTSThe lipid profile in cases were TC: 184.96 ± 24.85 mg/dL; TGL: 148.10 ± 32.71 mg/dL; HDL: 32.38 ± 5.78 mg/dL; LDL: 122.82 ± 24.76 mg/dL; VLDL: 29.68 ± 6.54 mg/dL. Correlation between eGFR shows a significant negative correlation with TC (p= 0.007), TGL (p= 0.002), LDL (p= 0.000) and VLDL (p= 0.002) and positive correlation with HDL (p= 0.000). Comparison of lipid profile with grades of eGFR shows significant association with TGL (f= 3.804, p= 0.004), HDL (f= 18.099, p= 0.000), LDL (f= 3.793, p=0.004) and VLDL (f= 3.631, p= 0.005), but not with TC (f= 2.194, p= 0.064). CONCLUSIONIn CKD depending on severity there is a rise in TC, TGL, LDL, VLDL and a fall in HDL depending on severity.

show abstract

mentioning

confidence: 99%

Dyslipidaemia in CKD Patients and Its Correlation With Severity of Renal Dysfunction

Mohanty¹,

Acharya²,

Thatoi³

et al. 2018

jemds

View full text Add to dashboard Cite

show abstract

“…In the general population, several clinical studies (e.g., AMORIS (Apolipoprotein-related MOrtality RISk) [38] or INTERHEART [39]) have shown that the ApoB/ApoA-I ratio is strongly correlated with cardiovascular events such as myocardial infarction and stroke [40].…”

Section: Journal Of Diabetes Researchmentioning

confidence: 99%

Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease

Vlad

Foia

Popescu

et al. 2019

Journal of Diabetes Research

View full text Add to dashboard Cite

Purpose. Nontraditional cardiovascular risk factors as apolipoprotein A (ApoA), apolipoprotein B (ApoB), and the proprotein convertase subtilisin/kexin type 9 (PCSK9) increase the prevalence of cardiovascular mortality in chronic kidney disease (CKD) or in end-stage renal disease (ESRD) through quantitative alterations. This review is aimed at establishing the biomarker (ApoA, ApoB, and PCSK9) level variations in uremic patients, to identify the studies showing the association between these biomarkers and the development of cardiovascular events and to depict the therapeutic options to reduce cardiovascular risk in CKD and ESRD patients. Methods. We searched the electronic database of PubMed, Scopus, EBSCO, and Cochrane CENTRAL for studies evaluating apolipoproteins and PCSK9 in CKD and ESRD. Randomized controlled trials, observational studies (including case-control, prospective or retrospective cohort), and reviews/meta-analysis were included if reference was made to those keys and cardiovascular outcomes in CKD/ESRD. Results. 18 studies met inclusion criteria. Serum ApoA-I has been significantly associated with the development of new cardiovascular event and with cardiovascular mortality in ESRD patients. ApoA-IV level was independently associated with maximum carotid intima-media thickness (cIMT) and was a predictor for sudden cardiac death. The ApoB/ApoA-I ratio represents a strong predictor for coronary artery calcifications, cardiovascular mortality, and myocardial infarction in CKD/ESRD. Plasma levels of PCSK9 were not associated with cardiovascular events in CKD patients. Conclusions. Although the “dyslipidemic status” in CKD/ESRD is not clearly depicted, due to different research findings, ApoA-I, ApoA-IV, and ApoB/ApoA-I ratio could be predictors of cardiovascular risk. Serum PCSK9 levels were not associated with the cardiovascular events in patients with CKD/ESRD. Probably in the future, the treatment of dyslipidemia in CKD/ESRD will be aimed at discovering new effective therapies on the action of these biomarkers.

show abstract

“…Disturbances in lipoprotein metabolism are evident even in the early stages of CKD and usually follow a downhill course that parallels the deterioration in renal function [11]. Severe lipid metabolism disorders arise in patients with kidney failure and the lipid metabolism disorder peculiar to this patient group is known as uremic dyslipidemia [11], which may accelerate its progression [12]. Abnormal lipid profile in CKD includes hypertriglyceridemia, increase in triglyceride remnant Lp (a), increase in very-low-density lipoprotein (VLDL), decrease in high density lipoprotein (HDL), total cholesterol (TC) and low-density lipoprotein (LDL) usually within normal limits except in nephrotic syndrome patients [13].…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of Lipid Profile in Patients of Non-Diabetic Chronic Kidney Disease in Relation to Its Severity

Behera¹

2020

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Chronic Kidney Disease (CKD) is a silent epidemic of the 21st century. Cardiovascular disease (CVD) is a major cause of morbidity and mortality among patients with CKD. This study aims to evaluate the type of dyslipidemia in CKD patients and correlates with the severity of renal dysfunction in CKD patients. Methods: The observational study was conducted in the Department of General Medicine, PRM MCH, Baripada between May 2018 and January 2019. 262 patients of CKD above 15 y of age, satisfying the inclusion and exclusion criteria were included in the study. Results: Out of 262 patients, 64.50% (169) were male and 35.50% (93) were females with M: F of 1.8:1. The age range was from 20 to 95. The average age of the patients in the study was 56.66+12.22 y. 45.04 % (118) of the patients were between 46 and 60 y of age. 68.70% of the patients had dyslipidemia. The comparison between lipid profiles of cases and controls showed a significant increase in total cholesterol, triglyceride, LDL and decrease in HDL. Conclusion: The prevalence of dyslipidemia in non-diabetic CKD is high. A high degree of abnormality is found in HDL with disease progression, which is statistically significant. Therefore, maintenance of desired lipid levels either through diet or early initiation of lipid-lowering drugs can be helpful in decreasing the risk of cardiovascular complications in CKD patients.

show abstract

Apolipoproteins: Good Markers for Cardiovacular Risk in Patients with Chronic Kidney Disease and Dyslipidemia

Abstract: Background and aims. Dyslipidemia (DLP) is a common complication of chronic kidney disease (CKD) and may accelerate its progression. Circulating lipoproteins and their constituent proteins, apolipoproteins, are risk factors for CKD and cardiovascular diseases (CVD

Cited by 4 publications

References 23 publications

Dyslipidaemia in CKD Patients and Its Correlation With Severity of Renal Dysfunction

Dyslipidaemia in CKD Patients and Its Correlation With Severity of Renal Dysfunction

Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease

Comparative Study of Lipid Profile in Patients of Non-Diabetic Chronic Kidney Disease in Relation to Its Severity

Contact Info

Product

Resources

About